| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.22B | 4.40B | 3.85B | 2.44B | 1.97B | 1.49B |
| Gross Profit | 1.63B | 1.64B | 1.33B | 836.88M | 682.26M | 527.74M |
| EBITDA | 1.00B | 928.12M | 723.50M | 301.35M | 175.09M | 115.44M |
| Net Income | 182.50M | 110.72M | -252.04M | -85.24M | -27.09M | -7.32M |
Balance Sheet | ||||||
| Total Assets | 7.28B | 7.08B | 7.69B | 6.59B | 2.82B | 2.65B |
| Cash, Cash Equivalents and Short-Term Investments | 325.40M | 335.97M | 334.26M | 208.69M | 138.77M | 343.45M |
| Total Debt | 3.70B | 3.77B | 3.92B | 3.51B | 1.49B | 1.35B |
| Total Liabilities | 5.47B | 5.46B | 5.91B | 5.04B | 2.28B | 2.00B |
| Stockholders Equity | 1.66B | 1.48B | 1.47B | 1.06B | 495.82M | 600.93M |
Cash Flow | ||||||
| Free Cash Flow | 499.74M | 577.64M | 417.25M | 10.67M | -106.03M | 27.38M |
| Operating Cash Flow | 633.32M | 668.50M | 582.41M | 162.64M | 183.34M | 156.30M |
| Investing Cash Flow | -183.01M | -236.82M | -173.15M | -3.21B | -291.99M | -125.93M |
| Financing Cash Flow | -426.35M | -418.12M | -370.00M | 3.13B | -102.13M | 272.70M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $627.84M | 156.97 | 3.74% | ― | 18.37% | ― | |
61 Neutral | $450.19M | 1.38 | ― | ― | 0.74% | ― | |
58 Neutral | $343.42M | 6.61 | 11.61% | ― | 2.14% | ― | |
54 Neutral | $593.87M | -11.14 | -44.33% | ― | 34.99% | -68.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $292.87M | -18.86 | -3.76% | ― | -22.14% | -787.87% | |
45 Neutral | $142.98M | -7.46 | -21.85% | ― | -16.54% | -119.56% |
On November 20, 2025, Auna S.A. announced its financial results for the third quarter of 2025, highlighting a mixed performance across its operations in Peru, Colombia, and Mexico. While the company saw growth in Peru and Colombia, with increased revenues and profitability in local currencies, Mexico faced challenges with declining revenues and profitability due to legacy issues and system migrations. Despite these challenges, Auna maintained a stable leverage ratio and completed a significant debt refinancing, positioning itself for future growth and operational improvements.
The most recent analyst rating on (AUNA) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Auna S.A. Class A stock, see the AUNA Stock Forecast page.
On November 20, 2025, Auna S.A. announced a strategic collaboration with Sojitz Corporation of America to explore joint business opportunities in the healthcare sector across Latin America, initially focusing on Mexico. This partnership aims to leverage Auna’s healthcare expertise and Sojitz’s investment capabilities to develop scalable and accessible healthcare infrastructure in the region. Previously, on September 24, 2025, Auna declared its intention to invest approximately $500 million over the next three to five years to expand its healthcare platform in Mexico, marking a significant step in its strategy to enhance healthcare access in Latin America.
The most recent analyst rating on (AUNA) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Auna S.A. Class A stock, see the AUNA Stock Forecast page.
On November 7, 2025, Auna S.A. announced the completion of a US$765 million debt refinancing, which strengthens its capital structure by extending debt maturities, reducing interest expenses, and enhancing liquidity. This refinancing involved issuing new Senior Secured 2032 Notes and a Term Loan, with significant participation from the International Finance Corporation. The transaction is expected to improve Auna’s financial position, aiding its strategic growth initiatives and expanding healthcare access in Latin America.
The most recent analyst rating on (AUNA) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Auna S.A. Class A stock, see the AUNA Stock Forecast page.
On November 4, 2025, Auna S.A. announced the successful pricing of $365 million in 8.750% Senior Secured Notes due 2032. The issuance, co-led with Oncosalud S.A.C., aims to fund a tender offer for its existing 10.000% Senior Secured Notes due 2029 and to prepay certain debts. This strategic financial move is expected to optimize Auna’s capital structure and enhance its financial flexibility, potentially strengthening its position in the Latin American healthcare market.
The most recent analyst rating on (AUNA) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Auna S.A. Class A stock, see the AUNA Stock Forecast page.
On November 3, 2025, Auna S.A. announced the early results of its cash tender offer and consent solicitation for its outstanding 10.000% senior secured notes due 2029. By October 31, 2025, approximately 73.39% of the notes had been validly tendered. The company has obtained the necessary consents to amend the indenture governing the notes, which will eliminate most restrictive covenants and certain default provisions. The early settlement date is expected around November 6, 2025, with the final settlement date anticipated by November 21, 2025. This move is part of Auna’s strategy to manage its debt obligations effectively.
The most recent analyst rating on (AUNA) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Auna S.A. Class A stock, see the AUNA Stock Forecast page.
On October 28, 2025, Auna S.A. announced a proposed offering of senior secured notes due in 2032, in collaboration with Oncosalud S.A.C. The proceeds from this private offering will be used to fund a tender offer to purchase its existing 10% Senior Secured Notes due 2029 and to prepay other indebtedness. This strategic financial move aims to optimize the company’s debt structure and support its ongoing operations in the healthcare sector.
The most recent analyst rating on (AUNA) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Auna S.A. Class A stock, see the AUNA Stock Forecast page.
On October 28, 2025, Auna S.A. released a report discussing its financial condition and results of operations for the first half of 2025. The company highlighted its commitment to expanding healthcare access and improving patient experiences through its unique ‘Auna Way’ operating model. This approach focuses on high-complexity care, leveraging technology, and strategic growth in key markets. The report also updated certain risk factors and disclosures from its previous annual report, reflecting Auna’s ongoing efforts to adapt to market demands and enhance its service offerings.
The most recent analyst rating on (AUNA) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Auna S.A. Class A stock, see the AUNA Stock Forecast page.
On October 20, 2025, Auna S.A. announced the commencement of a cash tender offer and consent solicitation for its outstanding 10.000% Senior Secured Notes due 2029. This move is aimed at purchasing the notes and amending the indenture governing them to eliminate restrictive covenants and certain default events. The tender offer, which expires on November 18, 2025, is part of Auna’s strategy to optimize its financial structure, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AUNA) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Auna S.A. Class A stock, see the AUNA Stock Forecast page.